Objective Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for
the treatment of diabetes. We aimed at describing the maximal benefits and risks associated …

According to the World Health Organization, cardiovascular disease (CVD) remains the
leading cause of death worldwide, accounting for approximately 18 million deaths per year …

In clinical practice, combined heart and liver dysfunctions coexist in the setting of the main
heart and liver diseases because of complex cardiohepatic interactions. It is becoming …

Non-alcoholic fatty liver disease (NAFLD) is one of the most common comorbidities
associated with overweight and metabolic syndrome (MetS). Importantly, NAFLD is one of its …

Objective Numerous studies have assessed the association between Nonalcoholic fatty liver
disease (NAFLD) and cardiovascular disease (CVD). However, results have been conflicting …

Studies have shown that nonalcoholic fatty liver disease (NAFLD) is strongly associated with
several metabolic disorders and diseases, such as obesity, type 2 diabetes mellitus, and …

Non-alcoholic fatty liver disease (NAFLD) is considered to be an independent
cardiovascular disease (CVD) risk factor. However, simple steatosis has a benign clinical …

Non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) are widespread diseases
and have multiple common risk factors and comorbidities. No studies of association between …

Background Modern lifestyles, especially high-caloric intake and physical inactivity,
contribute to the increased prevalence of non-alcoholic fatty liver disease (NAFLD), which …

Non-alcoholic fatty liver disease (NAFLD) is a burgeoning global health concern. In the
subset of NAFLD patients with non-alcoholic steatohepatitis (NASH), the presence of …